Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Biomarker tests in breast cancer: New study data indicate advantage for certain patients

2018-09-05 TAILORx is the first available study with long-term follow-up suitable for the assessment. The Oncotype DX test apparently identifies women who can omit chemotherapy.

read more Link to \Biomarker tests in breast cancer: New study data indicate advantage for certain patients\""

Continuous passive motion for knee or shoulder joints: advantage only in two therapeutic indications

2018-07-30 Less pain in stiff shoulders and improved mobility after total knee replacement – but the final report does not confirm greater benefit in rotator cuff tears.

read more Link to \Continuous passive motion for knee or shoulder joints: advantage only in two therapeutic indications\""

Haemophilia A and sialorrhoea: comparator therapies not implemented, added benefit not proven

2018-07-02 In two early benefit assessments, IQWiG was unable to derive an added benefit from the data presented because current standards of care were not implemented in the studies.

read more Link to \Haemophilia A and sialorrhoea: comparator therapies not implemented, added benefit not proven\""

Non-invasive prenatal diagnosis can reliably detect trisomy 21

2018-06-27 NIPD can reduce the number of invasive tests and hence the number of test-related miscarriages in women whose foetuses are at an increased risk of trisomy 21.

read more Link to \Non-invasive prenatal diagnosis can reliably detect trisomy 21\""

Prenatal testing of the foetal rhesus factor: test is reliable, but benefit is unclear

2018-05-15 The new non-invasive test, using a blood sample of the pregnant woman, is as reliable as the conventional test using a blood sample of the newborn. Studies on benefit and harm are still lacking.

read more Link to \Prenatal testing of the foetal rhesus factor: test is reliable, but benefit is unclear\""

Osteoporosis: guidelines cover almost all important health care aspects

2018-05-08 The search update for a possible disease management programme “osteoporosis” showed that integrated concepts of medical and physical rehabilitation were hardly addressed.

read more Link to \Osteoporosis: guidelines cover almost all important health care aspects\""

Systematic treatment of periodontal disease: advantage of further therapeutic approaches

2018-04-30 An indication or hint of greater benefit was now shown for six instead of two therapeutic measures. This applies particularly to the attachment level.

read more Link to \Systematic treatment of periodontal disease: advantage of further therapeutic approaches\""

Suitable methods for evidence syntheses with very few studies

2018-04-27 If only 2 to 4 studies are available, meta-analyses often do not lead to informative results. However, suitable methods for evidence syntheses are available, even in the event of sparse evidence.

read more Link to \Suitable methods for evidence syntheses with very few studies\""

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

No. Title Type Deadline
V18-01 Guideline synopsis for the DMP “type 2 diabetes” on the report plan 2018-09-13
N17-01A Negative pressure wound therapy for wounds healing by secondary Intention on the preliminary report 2018-09-25
S18-01 Newborn screening for sickle cell disease on the report plan 2018-10-02

Calls for tenders advertised

Calls for tenders advertised

In general, calls for tenders are published in German. Interested parties can check current calls for tenders on the German website.


Easily understandable information for patients and the general community

Rurioctocog alfa pegol (Adynovi) for the treatment of hemophilia A

Rurioctocog alfa pegol (trade name: Adynovi) has been approved in Germany since January 2018 for the treatment of hemophilia A in adults and children from 12 years of age. Hemophilia is an inherited disorder that affects the blood's ability to clot.   read more (Link to \Rurioctocog alfa pegol (Adynovi) for the treatment of hemophilia A\"" ‚Äì opens in a new window)


Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close